ASCP Corner: Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Lessons Learned
J Clin Psychiatry 2008;69(7):1184-1185
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Sequenced Treatment Alternatives to
Relieve Depression (STAR*D), the largest
prospective, randomized antidepressant
treatment trial to date in outpatients with
major depressive disorder (MDD) recruited
from real-world clinical settings, enrolling
4011 outpatients aged 18 to 75 years with
nonpsychotic MDD. Designed to determine
which treatments are most effective after
nonremission or intolerance to an initial selective
serotonin reuptake inhibitor (SSRI),
or to any of a series of subsequent randomized
treatments, STAR*D was conducted
in 18 primary and 23 psychiatric care settings
across the United States. This review
summarizes unique features of the study,
initial remission rates and associated participant
characteristics, remission rates for
subsequent treatment steps, relapse rates
during follow-up, and clinical implications.